Peer Review History

Original SubmissionSeptember 13, 2023
Decision Letter - Kahsu Gebrekidan, Editor

PONE-D-23-29407Predictors of non-adherence to antihypertensive medications: A cross-sectional study from a regional hospital in AfghanistanPLOS ONE

Dear Dr. Suwanbamrung,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Nov 19 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Kahsu Gebrekidan

Academic Editor

PLOS ONE

Journal requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. We note that the grant information you provided in the ‘Funding Information’ and ‘Financial Disclosure’ sections do not match. 

When you resubmit, please ensure that you provide the correct grant numbers for the awards you received for your study in the ‘Funding Information’ section.

3. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For more information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. 

In your revised cover letter, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

We will update your Data Availability statement on your behalf to reflect the information you provide.

4. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please move it to the Methods section and delete it from any other section. Please ensure that your ethics statement is included in your manuscript, as the ethics statement entered into the online submission form will not be published alongside your manuscript. 

Additional Editor Comments:

Please address the comments forwarded from both reviewers.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Cut off points for assessing depression status is not mentioned in methodology.

Cut-off points for assessing physical activity are not mentioned in methodology.

Class interval for age in Table (1) is not equal.

In Table (4), why 40 is used as cut off point for age.

Where is the p value for table (4)

Reviewer #2: Methodology

The authors should have explained the reliability and validity of the questionnaires used after translation to their local language. I would recommend doing a reliability analysis as a small measure before adding the full analysis of the study.

By translation of the questionnaires used and not stating the reliability this would jeopardize the results of the study.

Results

The authors didn’t consider in multiple medication asking the combined pills strategy. There is new drugs on the market with three active ingredients for hypertension or medication for hypertension. May be this could lead to more adherence to medication rather than multiple medications during the day and night time.

Discussion

The authors didn’t mention drug to drug interaction as a cause of non adherence in the presence of co morbidities.

Overall comment

The study is overall well planned and well written. The authors did a huge effort in combining three questionnaires in this study to get the results of the study.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Revision 1

Dear Editor,

We would like to thank the editorial board and the reviewers for their thoughtful evaluation of our manuscript entitled “Predictors of non-adherence to antihypertensive medications: A cross-sectional study from a regional hospital in Afghanistan”. Please find our revised manuscript (with tracked changes file), which we believe is substantially strengthened now that we have incorporated reviewers’ recommendations.

Journal requirements:

We made amendments according to the journal requirements.

Additional Editor Comments:

Please address the comments forwarded from both reviewers.

Response: Thank you so much. We present our point-by-point response to reviewers’ comments.

Response to Reviewers’ comments

Response to Reviewer 1 comments

1. Cut off points for assessing depression status is not mentioned in methodology.

Response: Thank you so much. We added the details for the cut off points for assessing the depression status in our study. Added details are:

The total scores were grouped into different categories of depression symptoms based on the following ranges: normal= 1–4, mild=5–9, moderate=10–14, severe=15–19, and extremely severe= 20-27 [34,35].

2. Cut-off points for assessing physical activity are not mentioned in methodology.

Response: Thank you. We added the details for the cut off points for assessing the physical activity level in our study.

We considered walking 3 days/week for at least 20 min/day to be low level of physical activity or < 3 metabolic equivalents (METs). Moderate physical activity 3-5days/week for at least 30 min/day represented medium level of physical activity or 3 to 7.9 METs. Vigorous physical activity 3-7 days/week signified high level of physical activity or >8.0 METs [36,37].

3. Class interval for age in Table (1) is not equal. In Table (4), why 40 is used as cut off point for age.

Response: Thank you so much. In table 1, we tried to primarily focus on distribution of age in our sample. In table 4, we focused to categorize age (<40, >40) for a modeling relationship based on relevant literature. This could help us to compare with other studies that have used a cut-off point similar to our one and as well as comparison among young age patients and old age patients.

4. Where is the p value for table (4)?

Response: Thank you so much for this suggestion. We have added p-values for both bivariate and multivariable analysis in Table 4.

Response to Reviewer 2 comments

Methodology

1. The authors should have explained the reliability and validity of the questionnaires used after translation to their local language. I would recommend doing a reliability analysis as a small measure before adding the full analysis of the study.

By translation of the questionnaires used and not stating the reliability this would jeopardize the results of the study.

Response: We thank you for this observation: we agree! We have taken your advice, and for each scale, we added the reliability analysis results to the manuscript. Additionally, we also have provided references for the validity and reliability of translated scales from other studies conducted in Afghanistan.

Results

2. The authors didn’t consider in multiple medication asking the combined pills strategy. There are new drugs on the market with three active ingredients for hypertension or medication for hypertension. May be this could lead to more adherence to medication rather than multiple medications during the day and night time.

Response: We thank you for this helpful comment. We agree that obtaining information about combined pill strategies from hypertensive patients could have offered additional insights into the factors affecting medication adherence. However, it is worth noting that Afghanistan has a low literacy level, and the responses from individuals there may be subject to recall bias. We have included additional information in the discussion section highlighting the significance of combined pill strategies and its preparation called fixed dose combinations as potential contributors to improved adherence.

Added details:

However, regimens with more than one medication per day are inconvenient, and as a consequence, patients find them difficult to follow, and potentially compromising the effectiveness of the treatment. Hence, the combination and preparation of the two AHMs as one tablet, known as a fixed-dose combination (FDC), might improve patient adherence [21,41]. Before prescribing FDCs, healthcare providers should carefully consider the medical history of patients, their current health status, and potential drug interactions.

Discussion

3. The authors didn’t mention drug-to-drug interaction as a cause of non-adherence in the presence of co morbidities.

Response: We thank you for this suggestion. We have added this important suggestion to the discussion section of our manuscript.

Added details:

Another limitation associated with comorbidities is the potential for drug-drug interactions, which can hinder medication adherence. It is crucial for healthcare providers to effectively communicate the risks and benefits of each medication, especially when potential interactions exist [21]. By understanding the significance, patients may be more motivated to adhere to the prescribed regimen and report any unusual side effects promptly [21,40]. Therefore, hypertensive patients with a comorbidity warrant adequate care, supervision and counseling during their treatment.

Overall comment

The study is overall well planned and well written. The authors did a huge effort in combining three questionnaires in this study to get the results of the study.

Response: We thank you for the constructive feedback. There is a large gap of health research in Afghanistan and we believe this study could be of potential importance for policy and make a baseline for future studies of medication adherence.

Best Regards,

Corresponding Author

Attachments
Attachment
Submitted filename: Response to Reviewers.docx
Decision Letter - Kahsu Gebrekidan, Editor

Predictors of non-adherence to antihypertensive medications: A cross-sectional study from a regional hospital in Afghanistan

PONE-D-23-29407R1

Dear Dr. Charuai,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Kahsu Gebrekidan

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #3: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #3: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #3: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #3: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #3: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: All the comments have been addressed carefully

1. Cut off points for assessing depression status is not mentioned in methodology.

Response: Thank you so much. We added the details for the cut off points for assessing the depression status in our study. Added details are:

The total scores were grouped into different categories of depression symptoms based on the following ranges: normal= 1–4, mild=5–9, moderate=10–14, severe=15–19, and extremely severe= 20-27 [34,35].

2. Cut-off points for assessing physical activity are not mentioned in methodology.

Response: Thank you. We added the details for the cut off points for assessing the physical activity level in our study.

We considered walking 3 days/week for at least 20 min/day to be low level of physical activity or < 3 metabolic equivalents (METs). Moderate physical activity 3-5days/week for at least 30 min/day represented medium level of physical activity or 3 to 7.9 METs. Vigorous physical activity 3-7 days/week signified high level of physical activity or >8.0 METs [36,37].

3. Class interval for age in Table (1) is not equal. In Table (4), why 40 is used as cut off point for age.

Response: Thank you so much. In table 1, we tried to primarily focus on distribution of age in our sample. In table 4, we focused to categorize age (<40, >40) for a modeling relationship based on relevant literature. This could help us to compare with other studies that have used a cut-off point similar to our one and as well as comparison among young age patients and old age patients.

4. Where is the p value for table (4)?

Response: Thank you so much for this suggestion. We have added p-values for both bivariate and multivariable analysis in Table 4.

Reviewer #3: Thank you for submitting manuscript and your hard work is really appreciated. Manuscript is clear, concise and well written. There is no any additional comments.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #3: No

**********

Formally Accepted
Acceptance Letter - Kahsu Gebrekidan, Editor

PONE-D-23-29407R1

PLOS ONE

Dear Dr. Suwanbamrung,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

If revisions are needed, the production department will contact you directly to resolve them. If no revisions are needed, you will receive an email when the publication date has been set. At this time, we do not offer pre-publication proofs to authors during production of the accepted work. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few weeks to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Kahsu Gebrekidan

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .